Summary: The GINA 2021 guidelines have confirmed several commonly followed practices in asthma treatment. These are widely accepted changes. Interestingly, it is worth adding that the huge choice of various inhalers might be confusing for some of us. Therefore, in this paper we summarize the current knowledge related to inhaler devices. The pros and cons of DPI and pMDI are briefly mentioned. We also highlight carbon footprint issues in asthma treatment. Despite changing guidelines and new medications, the milestone in the therapy of asthma and COPD is the acceptance of the treatment by the patient. As of today, we think some of the DPI inhalers might have better utilization and acceptance compared to pMDI.